Duke Molecular Physiology Institute Duke University School of Medicine Duke University Durham NC.
Department of Psychiatry and Behavioral Sciences Duke University Durham NC.
J Am Heart Assoc. 2019 Nov 5;8(21):e013228. doi: 10.1161/JAHA.119.013228. Epub 2019 Oct 23.
Background DNA methylation is implicated in many chronic diseases and may contribute to mortality. Therefore, we conducted an epigenome-wide association study (EWAS) for all-cause mortality with whole-transcriptome data in a cardiovascular cohort (CATHGEN [Catheterization Genetics]). Methods and Results Cases were participants with mortality≥7 days postcatheterization whereas controls were alive with≥2 years of follow-up. The Illumina Human Methylation 450K and EPIC arrays (Illumina, San Diego, CA) were used for the discovery and validation sets, respectively. A linear model approach with empirical Bayes estimators adjusted for confounders was used to assess difference in methylation (Δβ). In the discovery set (55 cases, 49 controls), 25 629 (6.5%) probes were differently methylated (<0.05). In the validation set (108 cases, 108 controls), 3 probes were differentially methylated with a false discovery rate-adjusted <0.10: cg08215811 (; log fold change=-0.14); cg17845532 (; fold change=-0.26); and cg17944110 (castor zinc finger 1 []; FC=0.26; <0.0001; false discovery rate-adjusted =0.046-0.080). Meta-analysis identified 6 probes (false discovery rate-adjusted <0.05): the 3 above, cg20428720 (intergenic), cg17647904 (), and cg23198793 (). Messenger RNA expression of 2 isoforms was lower in cases (fold change=-0.24 [=0.007] and fold change=-0.61 [=0.009]). The , , and transcripts did not show differential expression (>0.05); the transcript did not pass quality control. The cg17944110 probe is located within a potential regulatory element; expression of predicted targets (using GeneHancer) of the regulatory element, (=0.01) and (=0.03), were lower in cases. Conclusions We identified 6 novel methylation sites associated with all-cause mortality. Methylation in may serve as a regulatory element associated with mortality in cardiovascular patients. Larger studies are necessary to confirm these observations.
背景 DNA 甲基化与许多慢性疾病有关,可能与死亡率有关。因此,我们在心血管队列(CATHGEN[导管遗传学])中使用全转录组数据进行了全因死亡率的表观基因组关联研究(EWAS)。
方法和结果 病例是在导管插入术后≥7 天死亡的参与者,而对照者在随访≥2 年后仍存活。发现集和验证集分别使用 Illumina Human Methylation 450K 和 EPIC 阵列(Illumina,圣地亚哥,CA)。采用线性模型方法,使用经验贝叶斯估计器调整混杂因素,以评估甲基化差异(Δβ)。在发现组(55 例,49 例对照)中,有 25629 个(6.5%)探针存在甲基化差异(<0.05)。在验证组(108 例病例,108 例对照)中,有 3 个探针的差异甲基化经错误发现率校正后<0.10:cg08215811(<0.0001;校正后的错误发现率=0.046-0.080)。Meta 分析鉴定出 6 个探针(校正后的错误发现率<0.05):上述 3 个探针,cg20428720(基因间),cg17647904()和 cg23198793()。在病例中,2 个 亚型的信使 RNA 表达水平较低(FC=-0.24[=0.007]和 FC=-0.61[=0.009])。、、和 转录本未显示差异表达(>0.05); 转录本未通过质量控制。cg17944110 探针位于潜在的调控元件内;调控元件的预测靶点(使用 GeneHancer)的表达,和 (=0.01)和 (=0.03),在病例中较低。
结论 我们鉴定出 6 个与全因死亡率相关的新的甲基化位点。 中的甲基化可能作为与心血管患者死亡率相关的调节元件。需要更大的研究来证实这些观察结果。